STOCK TITAN

INTEGRA LIFESCIENCES HOLDINGS (IART) SEC Filings

IART NASDAQ

Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.

Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.

Rhea-AI Summary

Integra LifeSciences Holdings Corp (IART) reported that Invesco Ltd., as a parent holding company to its investment advisers, may be deemed to beneficially own 4,164,366 shares, or 5.4% of the class, held of record by its clients as of September 30, 2026. Invesco reported sole voting power over 4,164,293 shares and sole dispositive power over 4,164,366 shares, with no shared voting or dispositive power. It stated that no one person has greater than 5% economic ownership and that relevant clients have the right to receive dividends and sale proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
ownership
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2026 revenue of $411.2 million, compared with $402.1 million a year earlier, and net income of $14.9 million, versus a $5.4 million loss. For the nine months ended September 30, revenue was $1,221.9 million and net income was $14.7 million, compared with a $514.8 million loss in 2025; the prior-year period included a $511.4 million goodwill impairment charge. Net cash provided by operating activities for the nine-month period was $128.6 million, compared with $38.6 million in 2025.

In October 2026, the company completed a refinancing using a new credit agreement and a private offering of $450.0 million aggregate principal amount of 9.5% senior secured notes due 2033 to refinance its existing senior credit facility and pay related fees and expenses. The new agreement includes a $600.0 million Term Loan A facility, a $450.0 million Term Loan B facility and a $600.0 million revolving credit facility. The company also recognized a $19.0 million receivable for IEEPA tariff refunds and received $16.2 million in cash refunds and $0.7 million in cash interest receipts during the nine months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.60%
Tags
quarterly report
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2026 revenue of $411.2 million, up 2.3% reported and 2.5% organically year over year. GAAP net income was $14.9 million, versus a $5.4 million loss; adjusted diluted earnings per share were $0.59, versus $0.54. Specialty Surgery revenue rose 3.9%, while Tissue Reconstruction revenue declined 2.2%; results included an approximately $7 million revenue impact related to flooding at the Cincinnati facility. Operating cash flow was $96.0 million, compared with $40.9 million, and net debt was $1.5 billion at quarter-end.

On October 19, 2026, Integra completed a $2.1 billion debt refinancing, comprising a $1.65 billion senior secured credit facility and $450 million of 9.5% senior secured notes due 2033; proceeds repaid existing credit facilities and paid related fees and expenses. The company expects its effective interest rate to rise near the high end of the previously communicated 100- to 200-basis-point range. Fourth-quarter revenue guidance is $413 million to $433 million and adjusted diluted EPS is $0.61 to $0.71; full-year 2026 guidance is revenue of $1.634 billion to $1.654 billion and adjusted diluted EPS of $2.30 to $2.40.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
current report
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) completed a private offering of $450 million aggregate principal amount of 9.500% senior secured notes due November 1, 2033, and entered an amended and restated credit agreement making up to $1.65 billion available. The agreement includes a $600 million revolving facility and a $600 million Term Loan A, each with a five-year maturity, plus a $450 million Term Loan B with a seven-year maturity.

The Notes bear interest at 9.500% per year, payable semi-annually in arrears each May 1 and November 1, beginning May 1, 2027. Integra used a portion of the Notes proceeds and credit-agreement borrowings to repay in full all outstanding term and revolving loans, accrued interest and fees under its prior credit agreement; the prior revolving commitments were terminated, and the company incurred no early termination penalties. For Term SOFR borrowings, the Term Loan B applicable rate is 4.25%; the Revolving Facility and Term Loan A applicable rates are initially 3.00%, then range from 2.00% to 3.25% after delivery of the compliance certificate for the quarter ending December 31, 2026, based on the consolidated total leverage ratio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
current report
-
Rhea-AI Summary

Integra LifeSciences Holdings Corp. (IART) lists direct holdings reported by Andrea B. Caruso, CVP & CHRO, on October 1, 2026: 43,590 common shares. Her listed non-qualified options to buy common stock cover 4,375 shares at an exercise price of $43.3900; 2,634 at $68.1000; 2,674 at $65.1100; 3,244 at $52.8700; 4,634 at $36.2200; and 6,650 at $23.9500.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
insider
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation priced $450 million aggregate principal amount of 9.500% senior secured notes due 2033 in a private placement. The notes are general senior secured obligations, with guarantees from wholly owned domestic subsidiaries that guarantee the company’s senior secured credit facilities. The sale is expected to close on or about October 19, 2026, subject to customary closing conditions.

Integra intends to use the net proceeds, together with borrowings under a new credit facility, to refinance its existing credit facilities and pay related fees and expenses. The notes and guarantees have not been and will not be registered; they were offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A and certain non-U.S. persons outside the United States under Regulation S. Integra expects the notes’ interest rate, combined with anticipated rates on other refinancing elements, to increase its effective interest rate near the high end of the previously communicated 100–200 basis-point range.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
current report
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) reported preliminary, unaudited third-quarter 2026 expectations of $410 million to $412 million in revenue, adjusted earnings per diluted share of $0.55 to $0.59, and operating cash flow greater than $85 million. Flood-related supply disruptions at its Cincinnati facility are estimated to have reduced third-quarter revenue by approximately $7 million and are expected to negatively impact fourth-quarter revenue by approximately $15 million to $20 million.

Integra lowered its 2026 reported revenue outlook to $1.634 billion to $1.654 billion, from $1.654 billion to $1.695 billion, and adjusted earnings per diluted share guidance to $2.30 to $2.40, from $2.40 to $2.50. It expects full-year operating cash flow of approximately $190 million to $200 million. Integra expects insurance recoveries to mitigate a substantial portion of the disruption's earnings impact through the recovery period. The preliminary results remain subject to completion of financial closing procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.19%
Tags
current report
-
Rhea-AI Summary

Integra LifeSciences Holdings Corp. (IART) lists Lesha R. Shinn, CVP, Chief Legal Officer & Sec, as directly holding 26,838 shares of common stock as of September 17, 2026. The entry reports a holding position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
insider
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (IART) furnished an updated investor presentation used with prospective lenders as it prepares to refinance its senior credit facility in 2026. The company highlights 2026 as an inflection year while it completes FDA-mandated quality and manufacturing remediations and ramps a new Braintree, Massachusetts plant.

For the twelve months ended June 30, 2026, revenue was $1.648 billion, up 1.6% year over year, with adjusted EBITDA of $337 million, up 11.8% and representing a 20.5% margin, and adjusted gross margin of 62.5%. Operating cash flow was $85 million and free cash flow $26 million, recovering from a negative 2025 as remediation and capital spending begin to decline.

The presentation details multiple FDA warning letters, recalls, and a quality “compliance master plan,” with all warning-letter commitments targeted for completion in 2026 and full reintroduction by 2027 of products that historically generated about $150 million of annual revenue. Net leverage stands at 4.1x compliance adjusted EBITDA, above the stated 2.5–3.5x target, with management emphasizing future deleveraging as remediation costs, Braintree transition expenses, and EU MDR-related spending roll off.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
current report
Rhea-AI Summary

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported that executive vice president and chief human resources officer Chantal Veillon-Berteloot had 1,455 shares of Common Stock disposed of on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. The shares were treated as a non-derivative transaction at a reported price of $16.62 per share, and she now holds 20,772 shares directly. No Rule 10b5-1 trading plan is indicated for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.70%
Tags
insider

FAQ

How many INTEGRA LIFESCIENCES HOLDINGS (IART) SEC filings are available on StockTitan?

StockTitan tracks 64 SEC filings for INTEGRA LIFESCIENCES HOLDINGS (IART), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for INTEGRA LIFESCIENCES HOLDINGS (IART)?

The most recent SEC filing for INTEGRA LIFESCIENCES HOLDINGS (IART) was filed on November 10, 2026.